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Abstract
Background: Intestinal metaplasia (IM) is an important precursor lesion in the development of
gastric cancer (GC). The aim of this study was to investigate genetic factors previously linked to
GC risk for their possible association with IM. A total of 18 polymorphisms in 14 candidate genes
were evaluated in a Singapore-Chinese population at high risk of developing GC.
Methods: Genotype frequencies were compared between individuals presenting with (n = 128)
or without (n = 246) IM by both univariate and multivariate analysis.
Results: Carriers of the NQO1 609 T allele showed an association with IM in individuals who were
seropositive for Helicobacter pylori (HP+; OR = 2.61, 95%CI: 1.18-5.80, P = .018). The IL-10 819 C
allele was also associated with IM in HP+ individuals (OR = 2.32, 95%CI: 1.21-4.43, P = 0.011), while
the PTPN11 A allele was associated with IM in HP- individuals (OR = 2.51, 95%CI: 1.16-5.40, P =
0.019), but showed an inverse association in HP+ subjects (OR = 0.46, 95%CI: 0.21-0.99, P = 0.048).
Conclusion: Polymorphisms in NQO1, IL-10 and PTPN11, in combination with HP status, could be
used to identify individuals who are more likely to develop IM and therefore GC.
Background
Gastric cancer (GC) is the second leading cause of cancer-
related mortality worldwide, with more than 700,000
deaths annually[1]. The late presentation of this disease is
the main reason for the high mortality and highlights the
importance of early detection[2]. In Japan, mass screening
programs began in the 1960's and led to a significant
increase in the proportion of GC diagnosed at an early
stage from 8% in 1960-1964 to 50% in 1975-1979. How-
ever, more cost-effective screening programs that target
high risk groups are needed because of the limited
resources available in many Asian countries. Positive
Published: 13 October 2009
BMC Gastroenterology 2009, 9:76 doi:10.1186/1471-230X-9-76
Received: 19 June 2009
Accepted: 13 October 2009
This article is available from: http://www.biomedcentral.com/1471-230X/9/76
© 2009 Zhu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Gastroenterology 2009, 9:76 http://www.biomedcentral.com/1471-230X/9/76
Page 2 of 9
(page number not for citation purposes)
assessment of Helicobacter pylori (HP) infection can help to
identify high risk individuals since this is a proven risk fac-
tor for GC[3,4]. Various genetic factors have also been
associated with an increased risk for the development of
GC [5-8]. These polymorphisms could be used in con-
junction with HP status and together with dietary and
environmental factors to target screening programs
towards individuals deemed to be at high risk.
GC is thought to arise via a multi-step pathway that
involves intestinal metaplasia (IM) as a precursor
lesion[9]. It has been estimated that 0.25-1.1% of IM
lesions will progress to GC annually, representing an 18-
78-fold increased lifetime risk of developing this disease
in comparison to the general population[10,11]. In the
present study, we have investigated a panel of 18 poly-
morphisms in 14 candidate genes for their association
with IM precursor lesions in a Singapore-Chinese popula-
tion considered to be at increased risk of GC because of
age greater than 50 years. These polymorphisms were cho-
sen for study because previous research has shown them
to be risk factors for GC. They included SNPs in genes
involved in the immune response (IL-1β, IL-10, PTPN11)
[12-14], folate metabolism (FR-α, MTHFR)[15,16], cell
growth (EGF, HER2) [17-19], cell survival (STCH)[20],
cell invasion (MMP2)[21] and DNA damage or repair
(NQO1, SULT1A1, TP53, ADPRT) [22-26].
Methods
Subjects
Subjects were recruited from the Gastric Cancer Epidemi-
ology and Molecular Genetics Program (GCEP). This
project is a prospective cohort study aiming to enroll
4,000 Singapore-Chinese subjects aged more than 50
years from four major public hospitals in Singapore
(National University Hospital, Tan Tock Seng Hospital,
Singapore General Hospital, Changi General Hospital). It
offers screening by endoscopy and systematic follow-up
for a minimum of 5 years [27]. Chinese subjects older
than 50 years of age who met the following criteria were
eligible to enroll in the study: (i) symptoms of dyspepsia
(ie. bloating, distension, nausea, stomach pain etc), (ii)
family history of gastric cancer, or (iii) a medical condi-
tion that required them to undergo gastroscopy. They
must also be able to attend all study visits assigned to
them. Subjects who could not undergo gastroscopy, had a
history of stomach cancer or surgery, had a disabling ill-
ness, or were unable to provide informed consent were
ineligible for the study. Clinical information including
demographics, medical history and family history were
obtained. Informed consent was obtained from all sub-
jects and the study was approved by the institutional
review boards of all hospitals involved. Blood samples
from 374 individual subjects collected between April
2004 and December 2006 were used for genotyping in the
present study.
Three biopsies from the antrum, body and cardia were
collected for histopathological examination during each
endoscopic surveillance episode. IM was diagnosed from
mucosal biopsies in three locations (antrum, body and
cardia) for each subject and by consensus amongst three
pathologists according to the updated Sydney System for
the classification and grading of gastritis [28]. In cases
where H. pylori was identified in biopsies, eradication
therapy was administered according to standard clinical
guidelines. For 339/374 (91%) individuals, the HP status
was determined using the Helicoblot2.1 serology test
(Genelabs Diagnostics, Singapore). In individuals where
this test was not performed, the HP status was determined
from histological examination of biopsies from the
antrum, body and cardia, as well as from past medical his-
tory. Blood samples (8 mls) were collected into Vacu-
tainer CPT tubes (Becton Dickinson, Franklin Lakes, NJ)
and the mononuclear cells isolated and stored at -80°C
prior to DNA extraction using Tri-Reagent (MRC Inc,
Cincinnati, OH).
Helicoblot2.1 serology test
This serological assay uses a Western Blot nitrocellulose
strip containing electrophoretically separated proteins
from a bacterial lysate of an ulcer-causing type strain of H.
pylori and a recombinant antigen of H. pylori (Genelabs
Diagnostics, Singapore). When incubated with diluted
serum/plasma, specific antibodies to the various antigens,
if present, will bind to the H. pylori antigens on the strip.
These bound antibodies appear as dark bands upon reac-
tion with goat anti-human IgG conjugated with alkaline
phosphatase and a 5-bromo-4-chloro-2-indolyl-phos-
phate/nitroblue tetrazolium substrate solution. In order
to identify the various bands present, the strip is com-
pared with reference strips of non-reactive (negative) and
reactive (positive) controls run concurrently. Determina-
tion of H. pylori seropositivity was based on criteria rec-
ommended by the kit manufacturer. They consist of (1),
116 kD (CagA) positive band present with one or more of
the following bands: 89 kD (VacA), 37 kD, 35 kD, 30 kD
(UreA) and 19.5 kD together, or with the current infection
marker, (2) the presence of any one band at 89 kD (VacA),
37 kD or 35 kD, with or without current infection marker,
or (3) the presence of both 30 kD and 19.5 kD with or
without current infection marker.
Selection of gene polymorphism panel
A systematic literature search in PubMed was carried out
using the terms "gastric cancer" and "polymorphism".
From a total of 78 candidate polymorphisms identified,
18 were found to be significantly associated with the riskBMC Gastroenterology 2009, 9:76 http://www.biomedcentral.com/1471-230X/9/76
Page 3 of 9
(page number not for citation purposes)
of GC and were therefore included in the current investi-
gation of IM.
Genotyping
Table 1 shows the PCR primers, annealing temperatures
and product sizes for 17 SNPs investigated in this study by
pyroseqeuncing. The 86-bp variable number of tandem
repeats (VNTR) polymorphism in ILRN was genotyped
using PCR followed by size analysis using gel electro-
phoresis. The primers and PCR conditions were the same
as previously reported[29]. Polymorphisms were recorded
in their most commonly used notation for easy cross-ref-
erencing. For PCR, 50 ng DNA was amplified in a 25 μl
reaction containing 1 × FastStart Reaction Buffer, 2 mM
magnesium chloride, 10 μM deoxynucleotide mix, 500
nM each of the forward and reverse primers and 1 unit
FastStart Taq Polymerase (Roche Diagnostics, Mannheim,
Germany). PCR cycling comprised of 4 minutes at 95°C,
followed by 35 cycles of 30 seconds at 95°C, 30 seconds
at the appropriate annealing temperature and 30 seconds
at 72°C, before conclusion with 7 minutes at 72°C.
Pyrosequencing was performed by incubating the PCR
products with 3 μl of streptavidin magnetic beads (Amer-
sham Pharmacia Biotech, Uppsala, Sweden) and 1× bind-
ing buffer (10 mM Tris-HCl, 2 M NaCl, 1 mM EDTA, 0.1%
Tween 20) and mixing for 10 minutes at 37°C. The prod-
uct mix was then denatured by 5 seconds incubation in
0.2 M NaOH solution and washed in annealing buffer (20
mM Tris-acetate, 2 mM magnesium acetate) for 10 sec-
onds. The single-stranded products were transferred to an
annealing buffer containing 15 pmol of the sequencing
primer (Table 1) and incubated for 2 minutes at 80°C in
a Hybaid Maxi 14 hybridization oven (Thermo Electron,
USA). Pyrosequencing was then performed on a
PSQ96MA pyrosequencer instrument (Biotage AB, Upp-
sala, Sweden). Samples that failed to give a genotype
result after the first analysis were repeated up to two times.
Table 1: PCR primers and dispensation sequences for pyrosequencing of 17 SNPs evaluated for association with IM.
PCR Pyrosequencing
Locus Forward Primer Reverse Primer °C bp Sequencing Primer Dispensation
IL10 -- 1082 A/G CTCAATCAAAGGATCCCC
AGAGAC
AGGCTGGATAGGAGGTCC
CTTACT
60 253 ACACTACTAAGGCTTCT
TTG
cgagcagta
IL10 -- 819 T/C GGCCAATTTAATCCAAGG
TTT
TCTGCACTTGCTGAAAGC
TTCTTA
60 207 CCTTGTACAGGTCATGT
AA
gtcgatctc
IL-1B -- 511 T/C CATGAGATTGGCTAGGGT
AACAG
GCCCTCCCTGTCTGTATT
GA
60 230 CAATTGACAGAGAGCTC
C
atctgagca
MMP2 -- 1306 T/C TTTCATCTCTGGGCCATT
GT
TGAAGTTCTCCCTGTGAC
AACC
60 265 TCCCCACCCAGCACT gctgactct
EGF +61 A/G GTCATCCCTGCTTTCCTG
TGTG
CAGAGCAAGGCAAAGGCT
TAGA
60 266 CCCAATCCAAGGGTTGT cagactgac
PTPN11 (int1) A/G TGGACGAATGGCAAATTG GATCAATCCCACCTGAGA
CAGA
60 182 TTGTCTCTAAAGGACTG
TG
tgagctcat
NQ01 C609T AACTGCATGGAATTGGTT
GACTTA
TGGTGTCTCATCCCAAAT
ATTCT
60 191 GTGGCTTCCAAGTCTTA cgatcgtca
STCH rs2242661 AACTCGAATCCTGGACCT
GATTAG
CTGGCGTTTATAATCAAA
CCTGTG
65 203 GCGGAAAGAGAAAGG gctagtact
STCH rs1882881 CTATGGAAGGCTGCGAGA
AC
ACTTCCAGCTACAGGCAA
CATT
65 213 GAGGCTTTTTCCATCA gcagtcgtg
STCH rs12479 CTTGAAGGACCGTGTTGA
TGT'
GCAAAGGTCTCGGATAAC
AAAAA
60 312 ATGTTTCAGCACCAT gatagctag
STCH rs9982492 TCGTGCTTACCTTGTTCA
CATT
AGTATGAGCCCTGCCATG
A
60 193 CCACTTGTCCTTTAAGT
CC
actcgactc
SULT1A1 G638A GCCAGATCGCCTCTGAGG
T
TGGGGGACGGTGGTGTA
GT
65 233 CCTGGAGTTTGTGGG tgcgagctc
ADPRT T2285C GATACCTAAGTCGGGGGC
TTTC
ACAAGCTTTCCAGGAGAT
CCTAAC
65 262 TGCTCCTCCAGGCCA cagtctgat
HER2 +17ex17 A/G GTCCCTCCCACCCCAAAC
TA
CTGCCGTCGCTTGATGAG 65 145 CCCTCTGACGTCCAT gtcagatct
TP53 C215G TCCCAAGCAATGGATGAT
TTGA
AAGCCCAGACGGAAACC
GTAG
60 230 CAGAGGCTGCTCCCC tgcagtgct
FR-a A1314G AAGTGGAGACTGAGGCCC
AGA
TGACCCCTCCCCACCAAC 60 183 GTGTGGCCTGCTCAA cgagtacga
MTHFR C677T ACTGTCATCCCTATTGGC
AGGTTA
TCGGTGCATGCCTTCACA
A
60 168 GAAGGTGTCTGCGGG cgagtacgaBMC Gastroenterology 2009, 9:76 http://www.biomedcentral.com/1471-230X/9/76
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The genotyping success rate varied from 85-99% for the
18 polymorphisms.
Statistics
Univariate analyses were carried out by Pearson's chi-
square or the Fisher's exact test to examine for associations
between genotype distributions, IM status and clinical fac-
tors. As there were more than one polymorphism investi-
gated in IL10  and  STCH, the haplotypes were also
considered in the analyses. Variables found significantly
associated with IM in the univariate analyses for all cases,
and HP+ and HP- subgroups were entered in respective
multivariate logistic regression models. The analyses were
based on the assumption of a dominant genetic model.
All statistical analyses were performed using SPSS 16.0
(SPSS Inc., Chicago, IL) software at the 5% significance
level. The Woolf test was used to test for homogeneity of
OR between two strata. As each polymorphism was tested
for association with IM independently, it was not neces-
sary to control for the family-wise error rate. Thus, no
adjustment was made for multiple testing.
Results
The characteristics of 374 subjects evaluated in this study
are shown in Table 2. A total of 128 were diagnosed with
IM and 246 without IM. No significant differences
between IM+ and IM- groups were apparent for sex, family
history of GC (including 1st degree and 2nd degree rela-
tives), alcohol consumption (at least one unit of wine,
beer or liquor per week) or smoking status (at least one
cigarette per day for a minimum of one year). IM+ sub-
jects showed a significantly higher incidence of HP infec-
tion and were also older (P < 0.05).
Genotype frequencies for the 18 polymorphisms investi-
gated for association with IM are presented in Table 3. All
polymorphisms were in Hardy-Weinberg equilibrium (P
> 0.05), with the exception of IL10 -819T/C, NQO1 609C/
T and TP53 Arg72Pro. By univariate analysis, the NQO1
609 T allele was the only variant in the overall cohort that
was significantly associated with IM (OR = 1.82, 95%CI:
1.05-3.15,  P  = 0.032). In HP- individuals, only the
PTPN11 rs2301756 A allele was significantly associated
with IM (OR = 2.51, 95%CI: 1.16-5.40, P = 0.019). Three
polymorphisms in HP+ individuals were associated with
IM in univariate analysis: the IL-10 819 C allele (OR =
2.32, 95%CI: 1.21-4.43, P = 0.011), NQO1 609 T allele
(OR = 2.61, 95%CI: 1.18-5.80, P = 0.018) and PTPN11 A
allele (OR = 0.46, 95%CI: 0.21-0.99, P = 0.048). The hap-
lotypes in IL10 and STCH were not significantly associ-
ated with IM in overall cohort, HP-, as well as HP+ groups.
In multivariate analysis that included all cases, HP status
and age were significantly associated with IM, while the
NQO1 T allele showing borderline association (Table 4).
In HP- individuals, the PTPN11 A allele was the only fac-
tor associated with IM. However, in HP+ individuals the
factors of older age and the NQO1 609 T allele, IL-10 819
C allele and PTPN11 A allele were all significantly associ-
ated with IM. These results suggest that HP status is an
effect modifier of the association between IM and the
PTPN11 A allele (P = 0.002). As it is possible that IM+/HP-
cases in this study had prior unrecorded HP infection[30],
subgroup analysis on cases with a "revised HP+" status
(either HP+/IM-, HP+/IM+ or HP-/IM+) was also per-
formed. Age (OR = 2.10, 95%CI: 1.24-3.56, P = 0.006)
and IL-10 -819 C allele (OR = 1.82, 95%CI: 1.07-3.08, P =
0.027) were the only significant variables in this sub-
group.
Discussion
In this study, 18 polymorphisms that were previously
linked to GC were investigated for possible associations
with IM in a Singapore-Chinese population. The assump-
tion was made that IM represents a precursor lesion for
the development of GC and hence should have similar
genetic risk factors. The cohort evaluated here was consid-
ered to be at elevated risk for GC because of the selection
of individuals aged >50 years[27]. As expected, older indi-
viduals and those demonstrating seropositivity for HP
showed a doubling in the frequency of IM (Table 4).
Following univariate analysis, 3 genotypes were found to
be associated with IM. The NQO1 609 T allele was associ-
ated with IM, particularly in HP+ individuals. The IL-10 -
819 C allele was also significantly associated with IM in
HP+ cases. Interestingly, the PTPN11 A allele in intron 3
(rs2301756) was associated with increased incidence of
IM in HP- individuals but a decreased incidence in HP+
cases. In multivariate analysis, all 3 polymorphisms
remained significantly associated with IM, with the excep-
Table 2: Characteristics of study subjects in relation to the 
presence of IM.
Total (%) IM+ (%) IM- (%)
Subjects 374 128 246
Mean age ± SD (range) 60.5 ± 7.8 62.9 ± 7.8 59.2 ± 7.5
Age 50-59 yrs 190 (51) 48 (38)* 142 (58)*
Age 60-69 yrs 133 (36) 55 (43) 78 (32)
Age ≥70 yrs 51 (13) 25 (19) 26 (10)
Male 207 (55) 72 (56) 135 (55)
Family history of GC 66 (18) 23 (18) 43 (17)
HP infection 191 (51) 84 (66)* 107 (43)*
Drinker 66 (18) 22 (17) 46 (19)
Smoker 90 (24) 30 (23) 60 (24)
Chronic gastritis 290 (78) 115 (90) 175 (71)
Atrophy gastritis 194 (52) 97 (76) 97 (39)
Dysplasia 1 (0.3) 1 (0.8) 0
* P < 0.05BMC Gastroenterology 2009, 9:76 http://www.biomedcentral.com/1471-230X/9/76
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Table 3: Distribution of genotype frequencies according to IM and HP infection status
Gene polymorphism
(rs number)
Genotype IM- IM+ HP- HP+
IM- IM+ IM- IM+
ADPRT Val762Ala
(rs1136410)
TT 71 31 33 9 38 22
T C 1 1 7 6 06 42 45 33 6
CC 33 16 13 6 20 10
EGF +61A/G
(rs4444903)
A A 2 251 31 9 4
A G 1 0 3 5 55 42 04 93 5
G G 1 1 0 5 85 01 86 04 0
FR-α 1314A/G
(none)
G G 1 6 4 9 57 43 09 06 5
GA 74 31 43 12 31 19
A A 615011
HER2 Ile/Val
(rs1801200)
A A 1 7 4 9 28 73 28 76 0
AG 60 30 29 8 31 22
G G 111100
IL1RN 86-bp VNTR
(none)
44 212 101 112 33 100 68
24 28 18 9 4 19 14
3 4 120210
5 4 010001
2 2 220121
IL-1β -511C/T
(rs16944)
CC 64 35 33 10 31 25
C T 1 1 9 6 26 32 15 64 1
TT 48 23 20 10 28 13
IL-10 -819T/C
(rs1800871)
TT 131 55 57 21 74* 34
TC 78 46 39 15 39 31
CC 22 16 17 3 5 13
IL-10 -1082A/G
(rs1800896)
AA 207 100 98 37 109 63
AG 21 14 13 3 8 11
G G 202000
MMP2 -1306C/T
(rs243865)
C C 1 7 8 7 98 52 89 35 1
CT 46 22 26 8 20 14
T T 322012
MTHFR 667C/T
(rs1801133)
C C 1 3 2 7 76 42 36 85 4
CT 98 42 50 16 48 26
T T 1 4 78265
NQO1 609C/T
(rs1800566)
CC 64* 21 27 10 37* 11
C T 1 4 3 8 07 82 56 55 5
TT 28 22 13 4 5 18BMC Gastroenterology 2009, 9:76 http://www.biomedcentral.com/1471-230X/9/76
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tion of the NQO1 609 T allele which was associated with
borderline significance in the overall cohort (P = 0.056).
Previous data lends support to our observations. NQO1
(NAD(P)H: quinine oxidoreductase 1) codes for a
cytosolic enzyme that protects cells from oxidative dam-
age by preventing the generation of semiquinone free rad-
icals and reactive oxygen species[31]. The C to T
substitution at nucleotide 609 in exon 6 results in a
change of amino acid from Pro to Ser at codon 187[32].
Whereas the CC homozygous wildtype genotype (Pro/
Pro) has full enzymatic activity, the TT genotype (Ser/Ser)
completely lacks activity. The NQO1 609 TT genotype has
been associated with an increased risk for various tumour
types including gastrointestinal and urological cancers
[33-36]. An increased risk of GC in patients with a family
history of upper gastrointestinal cancers was also reported
for the NQO1 609 TT genotype in a study on Chinese sub-
jects[22]. Our observation of increased prevalence of IM
in carriers of the NQO1 609 T allele concurs with earlier
reports on its association with various cancers and can be
explained by a decreased activity for the detoxification of
environmental and dietary carcinogens.
TP53 Arg72Pro
(rs1042522)
CC 45 16 22 7 23 9
C G 1 2 6 7 86 62 36 05 5
GG 51 26 24 10 27 16
PTPN11 rs2301756
(rs2301756)
GG 175 85 92* 24 83* 61
GA 58 28 26 16 32 12
A A 420141
STCH rs12479
(rs12479)
G G 1 0 2 5 85 12 05 13 8
G A 1 0 6 3 95 21 25 42 7
AA 22 15 10 8 12 7
STCH rs1882881
(rs1882881)
AA 58 34 24 13 34 21
A C 1 2 3 5 86 71 55 64 3
CC 57 31 26 13 31 18
STCH rs2242661
(rs2242661)
AA 69 31 34 12 35 19
A G 1 0 6 4 65 21 35 43 3
GG 44 26 22 13 22 13
STCH rs9982492
(rs9982492)
CC 85 45 41 15 44 30
C T 1 0 5 3 95 31 25 22 7
TT 28 18 14 9 14 9
SULT1A1 638G/A
(rs9282861)
GG 221 108 112 33 109 75
GA 16 10 6 6 10 4
A A 101000
* Bold type denotes significant difference in genotype frequencies
Table 3: Distribution of genotype frequencies according to IM and HP infection status (Continued)
Table 4: Multivariate logistic regression analysis for associations 
with IM.
OR for IM
(95% CI)
P
All cases
HP (positive vs negative) 2.16 (1.35 - 3.45) 0.001
Age (>60 vs <60 yrs) 2.21 (1.40 - 3.49) 0.001
NQO1 (CT/TT vs CC) 1.74 (0.99 - 3.06) 0.056
HP- cases
Age (>60 vs <60 yrs) 1.92 (0.92 - 4.00) 0.082
PTPN11 (GA/AA vs GG) 2.51 (1.16 - 5.40) 0.019
HP+ cases
Age (≥60 vs <60 yrs) 2.19 (1.15 - 4.17) 0.017
NQO1 (CT/TT vs CC) 2.61 (1.18 - 5.80) 0.018
IL-10 -819 (TC/CC vs TT) 2.32 (1.21 - 4.43) 0.011
PTPN11 (GA/AA vs GG) 0.46 (0.21 - 0.99) 0.048BMC Gastroenterology 2009, 9:76 http://www.biomedcentral.com/1471-230X/9/76
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The NQO1 C609T polymorphism was previously associ-
ated with seropositivity to HP in a Japanese study[37],
thus raising the possibility that it is an indirect risk factor
for IM via association with HP infection. However, we
found no association between the NQO1  C609T poly-
morphism and HP infection in the present cohort (results
not shown).
Carriers of the IL-10 -819 C allele express higher mucosal
levels of IL-10 (interleukin 10) mRNA and experience col-
onization with more virulent HP strains[38]. Similar to
NQO1 C609T, no association was observed here between
the IL-10 T-819C polymorphism and HP infection. The
current result showing the IL-10 -819 C allele is associated
with IM is at odds with an Italian study that reported the
TT genotype was associated with increased risk of IM[29]
However, two studies in Chinese and German popula-
tions found no associations between IL-10 T-819C and
IM[38,39].
Other common polymorphisms in the IL-1β and TNF-α
cytokine genes have been proposed to influence the host
response to HP and therefore the risk of developing
GC[13,29,38-42]. The IL-1β C-511T and IL-10 A-1082G
polymorphisms were investigated in this cohort, but no
significant associations were found with seropositivity to
HP or with the presence of IM (Table 3). Previous studies
reported the IL-1β -511 T allele increased the risk of IM in
some[38,39], but not all populations[12]. One study
found an association between the IL-10 A-1082G poly-
morphism and IM[12,43], but 3 other studies did
not[12,29,39].
PTPN11 (protein tyrosine phosphatase, non-receptor type
11) encodes for SHP-2, a protein tyrosine phosphatase
thought to play a key role in intracellular signaling elicited
by growth factors and cytokines[44]. Interactions between
the HP cagA protein and SHP-2 in gastric epithelial cells
are believed to contribute to the development of GC[45]
The PTPN11 AA genotype was associated with reduced
risk of gastric atrophy in a Japanese population of HP
seropositive individuals [14,30]. In those studies, the
assessment of gastric atrophy was done with serology test
(pepsinogen levels). The present results on IM in HP sero-
positive Singapore-Chinese support these earlier observa-
tions, although the number of AA genotype individuals (n
= 6) did not allow separate evaluation of this group. The
diagnosis of IM was based on histology examination. The
PTPN11 intron 3 G/A SNP may be in linkage disequilib-
rium with a coding marker that influences the interaction
of SHP-2 with cagA and subsequent downstream signal-
ing. However, its association with increased frequency of
IM in HP negative individuals suggests it may play a role
independently of this factor.
Conclusion
In summary, we found 3 polymorphisms associated with
IM in a Singapore-Chinese population that was at high
risk for GC because of older age and seropositivity for HP.
The value of these SNPs in facilitating more cost-effective
surveillance programs awaits further validation in large,
independent cohorts.
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